Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Onxeo SA (C4X) - Net Assets
Latest net assets as of December 2024: €-8.27 Million EUR
Based on the latest financial reports, Onxeo SA (C4X) has net assets worth €-8.27 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€17.93 Million) and total liabilities (€26.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-8.27 Million |
| % of Total Assets | -46.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | -128.46% |
| 10-Year Change | -108.04% |
| Growth Volatility | 427.05 |
Onxeo SA - Net Assets Trend (2013–2024)
This chart illustrates how Onxeo SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Onxeo SA (2013–2024)
The table below shows the annual net assets of Onxeo SA from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-8.27 Million | -155.83% |
| 2023-12-31 | €14.80 Million | -33.52% |
| 2022-12-31 | €22.27 Million | -32.40% |
| 2021-12-31 | €32.94 Million | +13.45% |
| 2020-12-31 | €29.04 Million | +68.84% |
| 2019-12-31 | €17.20 Million | -62.12% |
| 2018-12-31 | €45.40 Million | -8.97% |
| 2017-12-31 | €49.87 Million | -46.99% |
| 2016-12-31 | €94.09 Million | -8.47% |
| 2015-12-31 | €102.80 Million | -15.72% |
| 2014-12-31 | €121.97 Million | +1446.21% |
| 2013-12-31 | €7.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Onxeo SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3087238600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €37.27 Million | % |
| Total Equity | €-8.93 Million | 100.00% |
Onxeo SA Competitors by Market Cap
The table below lists competitors of Onxeo SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RELATECH S.P.A.
F:8EP
|
$49.81 Million |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
$49.84 Million |
|
Socar Inc.
KO:403550
|
$49.84 Million |
|
Daemyoung Energy Co Ltd
KQ:389260
|
$49.84 Million |
|
Mi Chang Oil
KO:003650
|
$49.79 Million |
|
Fynske Bank A/S
CO:FYNBK
|
$49.79 Million |
|
Avantium Holding BV
AS:AVTX
|
$49.78 Million |
|
AGF A/S NAM.
F:5IN
|
$49.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onxeo SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,805,000 to -8,930,000, a change of -23,735,000 (-160.3%).
- Net loss of 23,931,000 reduced equity.
- New share issuances of 24,000 increased equity.
- Other factors increased equity by 172,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.93 Million | -267.98% |
| Share Issuances | €24.00K | +0.27% |
| Other Changes | €172.00K | +1.93% |
| Total Change | €- | -160.32% |
Book Value vs Market Value Analysis
This analysis compares Onxeo SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.98 | €0.12 | x |
| 2018-12-31 | €0.85 | €0.12 | x |
| 2019-12-31 | €0.28 | €0.12 | x |
| 2020-12-31 | €0.37 | €0.12 | x |
| 2021-12-31 | €0.36 | €0.12 | x |
| 2022-12-31 | €0.20 | €0.12 | x |
| 2023-12-31 | €0.10 | €0.12 | x |
| 2024-12-31 | €-0.06 | €0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Onxeo SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1334.69%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -194.27% | -1044.82% | 0.08x | 2.25x | €-16.11 Million |
| 2014 | -6.31% | -34.87% | 0.15x | 1.25x | €-19.90 Million |
| 2015 | -18.88% | -557.57% | 0.03x | 1.26x | €-29.69 Million |
| 2016 | -24.10% | -512.45% | 0.04x | 1.33x | €-32.08 Million |
| 2017 | -118.44% | -621.47% | 0.12x | 1.57x | €-64.06 Million |
| 2018 | -20.70% | -153.40% | 0.10x | 1.39x | €-13.94 Million |
| 2019 | -196.13% | -786.57% | 0.11x | 2.19x | €-35.45 Million |
| 2020 | 3.75% | 61.32% | 0.04x | 1.60x | €-1.81 Million |
| 2021 | -18.02% | -146.16% | 0.08x | 1.61x | €-9.23 Million |
| 2022 | -87.84% | -1355.65% | 0.03x | 1.93x | €-21.79 Million |
| 2023 | -137.41% | -1130.22% | 0.05x | 2.38x | €-21.82 Million |
| 2024 | 0.00% | -1334.69% | 0.10x | 0.00x | €-23.04 Million |
Industry Comparison
This section compares Onxeo SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onxeo SA (C4X) | €-8.27 Million | -194.27% | N/A | $49.80 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |